PARP1 and triple-negative breast carcinoma: Furthermore, HDAC inhibitors have been shown to enhance the sensitivity of cancers, such as triple-negative breast cancer and prostate cancer, to PARP inhibitors, suggesting their potential in combination therapies [31].